ArticleMolecules (Basel, Switzerland)2025
Novel Ruthenacarborane-NSAID Conjugates.
Sonam Sonam, Marija Mojić, Vuk Gordić, Markus Laube, Jonas Schädlich, Jens Pietzsch, Adrian Nicoara, Luiza Gaina, Sanja Mijatović, Danijela Maksimović-Ivanić and 2 more
Abstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Sonam SonamInstitute of Bioanalytical Chemistry Centre for Biotechnology and Biomedicine (BBZ), Faculty of Chemistry, Leipzig University, Deutscher Platz 5, 04103 Leipzig, Germany.
Marija MojićInstitute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia.ORCID 0000-0002-4906-9880 Vuk GordićInstitute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia.ORCID 0009-0006-6382-6063 Markus LaubeDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Bautzner Landstraße 400, 01328 Dresden, Germany.ORCID 0000-0003-4916-3794 Jonas SchädlichDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Bautzner Landstraße 400, 01328 Dresden, Germany.ORCID 0009-0002-4550-0394 Jens PietzschDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Bautzner Landstraße 400, 01328 Dresden, Germany.ORCID 0000-0002-1610-1493 Adrian NicoaraFaculty of Chemistry and Chemical Engineering, Babeş-Bolyai University, Str. Arany Janos Nr. 11, RO-400028 Cluj-Napoca, Romania.ORCID 0000-0003-0534-4390 Luiza GainaFaculty of Chemistry and Chemical Engineering, Babeş-Bolyai University, Str. Arany Janos Nr. 11, RO-400028 Cluj-Napoca, Romania.ORCID 0000-0002-1328-0107 Sanja MijatovićInstitute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia.ORCID 0000-0001-9509-9098 Danijela Maksimović-IvanićInstitute for Biological Research "Siniša Stanković", National Institute of Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia.ORCID 0000-0002-8006-5079 Goran N KaluđerovićDepartment of Engineering and Natural Sciences, University of Applied Sciences Merseburg, Eberhard-Leibnitz-Str. 2, 06217 Merseburg, Germany.ORCID 0000-0001-5168-1000 Evamarie Hey-HawkinsInstitute of Bioanalytical Chemistry Centre for Biotechnology and Biomedicine (BBZ), Faculty of Chemistry, Leipzig University, Deutscher Platz 5, 04103 Leipzig, Germany.ORCID 0000-0003-4267-0603 Funding
Bundesministerium für Forschung, Technologie und Raumfahrt No. 031L0258BDeutsche Forschungsgemeinschaft HE 1376/54-1Deutsche Forschungsgemeinschaft PI 304/7-1Deutsche Forschungsgemeinschaft SFB/TRR 205/2 (No. 314061271)European Union - NextGenerationEU PNRR-III-C9-2023-I8-CF, contract nr. 760240/28.12.2023Federal Ministry of Education and Research and the Federal State of Saxony-Anhalt 03FHP155DMinistry of Science, Technological Development, and Innovation of the Republic of Serbia No. 451-03-136/2025-03/200007Romanian Ministry of Research, Innovation and Digitalization NRR-III-C9-2023-I8-CF, contract nr. 760240/28.12.2023
6 · The paper itselfAbstract
The significant side effects associated with platinum-based anticancer agents have driven the continuous pursuit of novel, non-platinum-based metal compounds. Ruthenium-based organometallic compounds have emerged as promising alternatives, owing to their distinctive and adaptable biochemical properties. The research efforts are focused on the development of ruthenacarborane-based anticancer drugs. The combination of ruthenium(II) complexes, recognized for their inherent anticancer potential, with carboranes, boron-rich clusters possessing unique chemical and physical characteristics, and NSAIDs, known to inhibit COX, an enzyme overexpressed in tumors, offers a novel approach for cancer therapy. Consequently, combining these three moieties into a single molecule represents a compelling strategy to develop drugs with a dual mode of action. Herein, we report the synthesis of a series of ruthenacarborane-(
Indexed as
Anti-Inflammatory Agents, Non-SteroidalAntineoplastic AgentsBoranesRutheniumCell Line, TumorCyclooxygenase InhibitorsHumansMolecular StructureAnti-Inflammatory Agents, Non-SteroidalAntineoplastic AgentsBoranesCyclooxygenase InhibitorsRutheniumcyclic voltammetry (CV)cyclooxygenase (COX)non-steroidal anti-inflammatory drugs (NSAIDs)ruthenacarborane
Identifiers
PMID41226118
PMCPMC12608622
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390